Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17114042 | 0.90 | ALDH1A1 (0.47) | ALDH1A1GAAKMT2APOLBAADAT | |
| SCHEMBL20437117 | 0.79 | ALDH1A1 (0.59) | ALDH1A1GAAKMT2APOLBAADAT | |
| SCHEMBL17114021 | 0.75 | POLB (0.71) | ALDH1A1GAAKMT2APOLBAADAT | |
| SCHEMBL20437112 | 0.71 | MAP3K5 (0.40) | ALDH1A1GAAKMT2APOLBAADAT | |
| SCHEMBL31531012 | 0.71 | ALDH1A1 (0.63) | ALDH1A1GAAKMT2APOLBAADAT | |
| SCHEMBL14064744 | 0.70 | SIRT5 (0.65) | ALDH1A1KMT2ATSHRCYP2C9CYP2D6 | |
| SCHEMBL17114031 | 0.68 | ALDH1A1 (0.45) | ALDH1A1GAAKMT2APOLBAADAT | |
| SCHEMBL20246861 | 0.65 | ALDH1A1 (0.82) | ALDH1A1GAAKMT2APOLBAADAT | |
| SCHEMBL29569430 | 0.64 | ALDH1A1 (0.61) | ALDH1A1GAAKMT2APOLBAADAT | |
| SCHEMBL478614 | 0.63 | ALDH1A1 (1.00) | ALDH1A1GAAKMT2APOLBAADAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180215709-A1 | TYPE III DEIODINASE INHIBITORS AND USES THEREOF | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215709-A1 | TYPE III DEIODINASE INHIBITORS AND USES THEREOF | TPO, DPP3, HSD17B3 | ALDH1A1 212/4885GAA 768/4885KMT2A 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.